PT1608647E - Derivados de 5-feniltiazole e sua utilização como inibidores da quinase p13 - Google Patents
Derivados de 5-feniltiazole e sua utilização como inibidores da quinase p13 Download PDFInfo
- Publication number
- PT1608647E PT1608647E PT04717567T PT04717567T PT1608647E PT 1608647 E PT1608647 E PT 1608647E PT 04717567 T PT04717567 T PT 04717567T PT 04717567 T PT04717567 T PT 04717567T PT 1608647 E PT1608647 E PT 1608647E
- Authority
- PT
- Portugal
- Prior art keywords
- kinase inhibitors
- compounds
- phenylthiazole derivatives
- phenylthiazole
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0305152.1A GB0305152D0 (en) | 2003-03-06 | 2003-03-06 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1608647E true PT1608647E (pt) | 2008-03-27 |
Family
ID=9954250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT04717567T PT1608647E (pt) | 2003-03-06 | 2004-03-05 | Derivados de 5-feniltiazole e sua utilização como inibidores da quinase p13 |
Country Status (15)
Country | Link |
---|---|
US (1) | US8017608B2 (pt) |
EP (1) | EP1608647B1 (pt) |
JP (1) | JP4382085B2 (pt) |
CN (1) | CN100569770C (pt) |
AT (1) | ATE383358T1 (pt) |
AU (1) | AU2004218239B2 (pt) |
BR (1) | BRPI0408068A (pt) |
CA (1) | CA2517708A1 (pt) |
DE (1) | DE602004011199T2 (pt) |
ES (1) | ES2297393T3 (pt) |
GB (1) | GB0305152D0 (pt) |
MX (1) | MXPA05009468A (pt) |
PL (1) | PL1608647T3 (pt) |
PT (1) | PT1608647E (pt) |
WO (1) | WO2004078754A1 (pt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
SE0402735D0 (sv) * | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
EA015628B1 (ru) * | 2005-05-24 | 2011-10-31 | Мерк Сероно С.А. | Производные тиазола и их применение |
WO2006125803A1 (en) * | 2005-05-24 | 2006-11-30 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
AU2006258101A1 (en) * | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
NZ565749A (en) | 2005-08-26 | 2010-12-24 | Serono Lab | Pyrazine derivatives and use as PI3K inhibitors |
GB2431156A (en) * | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
US20090029997A1 (en) * | 2006-01-23 | 2009-01-29 | Laboratoires Serono Sa | Thiazole Derivatives and Use Thereof |
WO2007129044A1 (en) * | 2006-05-03 | 2007-11-15 | Astrazeneca Ab | Thiazole derivatives and their use as anti-tumour agents |
GB0608854D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | P13 kinase inhibitors |
WO2008027584A2 (en) * | 2006-09-01 | 2008-03-06 | Vertex Pharmaceuticals Incorporated | 5- (2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase |
GB0620059D0 (en) | 2006-10-10 | 2006-11-22 | Ucb Sa | Therapeutic agents |
GB0620818D0 (en) * | 2006-10-19 | 2006-11-29 | Ucb Sa | Therapeutic agents |
KR20090110950A (ko) | 2007-02-22 | 2009-10-23 | 메르크 세로노 에스. 에이. | (피라진 유도체) 퀴녹살린 화합물 및 이의 용도 |
CN101820757A (zh) | 2007-06-01 | 2010-09-01 | 普林斯顿大学托管委员会 | 通过调节宿主细胞代谢途径治疗病毒感染 |
GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
PE20091523A1 (es) | 2007-12-20 | 2009-10-29 | Novartis Ag | Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k) |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
US20110224187A1 (en) * | 2008-10-16 | 2011-09-15 | Anandan Palani | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof |
US8609666B2 (en) | 2009-02-12 | 2013-12-17 | Merck Serono Sa | 2-morpholino-pyrido[3,2-D]pyrimidines |
JP2012531454A (ja) | 2009-07-02 | 2012-12-10 | ノバルティス アーゲー | Pi3k阻害剤として有用な2−カルボキサミドシクロアミノウレア類 |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
DK2496567T3 (en) * | 2009-11-05 | 2017-10-30 | Rhizen Pharmaceuticals S A | PRESENT UNKNOWN BENZOPYRANKINA MODULATORS |
KR20130049766A (ko) | 2009-11-13 | 2013-05-14 | 메르크 세로노 에스. 에이. | 트리사이클릭 피라졸 아민 유도체 |
NZ601581A (en) | 2010-02-03 | 2014-03-28 | Signal Pharm Llc | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
US9255072B2 (en) * | 2011-03-04 | 2016-02-09 | National Health Rsearch Institutes | Pyrazole compounds and thiazole compounds as protein kinases inhibitors |
RS58326B1 (sr) * | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Nova jedinjenja kao modulatori proteinskih kinaza |
AU2012290056B2 (en) | 2011-08-03 | 2015-03-19 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for LKB1 status |
CN102633748A (zh) * | 2012-03-22 | 2012-08-15 | 盛世泰科生物医药技术(苏州)有限公司 | 2-甲酸乙酯-5-溴-1,3,4-噻二唑的合成方法 |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
CA2909625C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
SG11201508527VA (en) | 2013-04-17 | 2015-11-27 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
US9358232B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
BR112015026257B1 (pt) | 2013-04-17 | 2022-12-20 | Signal Pharmaceuticals, Llc | Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit |
EP2986298A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Treatment of cancer with dihydropyrazino-pyrazines |
WO2014172425A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
BR112015026247B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de compostos em combinação com um análogo de citidina, composição farmacêutica que os compreende, e kit |
CN113831345A (zh) | 2013-05-29 | 2021-12-24 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
EP3419980A4 (en) * | 2016-02-26 | 2019-07-03 | The Board of Trustees of the Leland Stanford Junior University | INHIBITORS OF PI-KINASE WITH ANTI-INFECTIOUS ACTIVITY |
JOP20190052A1 (ar) * | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز |
AU2018289539B2 (en) | 2017-06-22 | 2024-07-04 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |
WO2022017371A1 (zh) * | 2020-07-21 | 2022-01-27 | 中国医药研究开发中心有限公司 | 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL355639A1 (en) * | 1999-09-10 | 2004-05-04 | Merck & Co, Inc. | Tyrosine kinase inhibitors |
JP4820518B2 (ja) * | 2000-01-24 | 2011-11-24 | アストラゼネカ アクチボラグ | モルホリノ置換化合物治療薬 |
TWI314928B (en) * | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
-
2003
- 2003-03-06 GB GBGB0305152.1A patent/GB0305152D0/en not_active Ceased
-
2004
- 2004-03-05 AU AU2004218239A patent/AU2004218239B2/en not_active Ceased
- 2004-03-05 EP EP04717567A patent/EP1608647B1/en not_active Expired - Lifetime
- 2004-03-05 ES ES04717567T patent/ES2297393T3/es not_active Expired - Lifetime
- 2004-03-05 US US10/547,691 patent/US8017608B2/en not_active Expired - Fee Related
- 2004-03-05 WO PCT/EP2004/002285 patent/WO2004078754A1/en active IP Right Grant
- 2004-03-05 MX MXPA05009468A patent/MXPA05009468A/es active IP Right Grant
- 2004-03-05 PT PT04717567T patent/PT1608647E/pt unknown
- 2004-03-05 CA CA002517708A patent/CA2517708A1/en not_active Abandoned
- 2004-03-05 PL PL04717567T patent/PL1608647T3/pl unknown
- 2004-03-05 JP JP2006500054A patent/JP4382085B2/ja not_active Expired - Lifetime
- 2004-03-05 DE DE602004011199T patent/DE602004011199T2/de not_active Expired - Lifetime
- 2004-03-05 BR BRPI0408068-8A patent/BRPI0408068A/pt not_active IP Right Cessation
- 2004-03-05 AT AT04717567T patent/ATE383358T1/de active
- 2004-03-05 CN CNB2004800117772A patent/CN100569770C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2004218239B2 (en) | 2007-02-22 |
EP1608647A1 (en) | 2005-12-28 |
CA2517708A1 (en) | 2004-09-16 |
MXPA05009468A (es) | 2006-02-13 |
AU2004218239A1 (en) | 2004-09-16 |
ATE383358T1 (de) | 2008-01-15 |
CN1780832A (zh) | 2006-05-31 |
GB0305152D0 (en) | 2003-04-09 |
CN100569770C (zh) | 2009-12-16 |
JP4382085B2 (ja) | 2009-12-09 |
WO2004078754A1 (en) | 2004-09-16 |
US8017608B2 (en) | 2011-09-13 |
ES2297393T3 (es) | 2008-05-01 |
DE602004011199D1 (de) | 2008-02-21 |
BRPI0408068A (pt) | 2006-02-14 |
US20060148822A1 (en) | 2006-07-06 |
JP2006515343A (ja) | 2006-05-25 |
DE602004011199T2 (de) | 2009-01-02 |
EP1608647B1 (en) | 2008-01-09 |
PL1608647T3 (pl) | 2008-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1608647E (pt) | Derivados de 5-feniltiazole e sua utilização como inibidores da quinase p13 | |
MY156407A (en) | 5-phenylthiazole derivatives and use as p13 kinase inhibitors | |
TNSN05278A1 (en) | Inhibitors of phosphatidylinositol 3-kinase | |
TNSN06064A1 (en) | 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases | |
MXPA05010712A (es) | Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias. | |
TW200801003A (en) | Novel compounds | |
SE0300480D0 (sv) | Novel compounds | |
SE0202539D0 (sv) | Compounds | |
SE0200920D0 (sv) | Novel compounds | |
TW200514776A (en) | Aminotriazole compounds useful as inhibitors of protein kinases | |
TW200613243A (en) | Novel compounds | |
MY149512A (en) | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | |
TW200738659A (en) | Novel compounds | |
TW200639156A (en) | New compounds | |
AU2006273692A8 (en) | 1,4-Dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
SE0302139D0 (sv) | Novel compounds | |
MY135850A (en) | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | |
NO20053809L (no) | Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav | |
TW200604197A (en) | New compounds | |
WO2007068473A3 (en) | Organic compounds | |
SE0401763D0 (sv) | Compounds | |
EA200600992A1 (ru) | Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение | |
SE0302755D0 (sv) | Novel compounds | |
SE0202692D0 (sv) | Compounds | |
SG146685A1 (en) | Dihydroporphine derivatives, processes for their preparation, and pharmaceutical compositions containing them |